Ping Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ping Huang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Yafeng Wan
Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing, China
3 shared publicationsZiyao Wang
National Key Clinical Department, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing 400000, P.R. China
3 shared publicationsXiaolong Chen
National Key Clinical Department, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publicationsZhixiong Xia
Department of Pathology, The Center Hospital of Wuhan, Hubei, China
2 shared publicationsDan Song
National Key Clinical Department, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing 400000, P.R. China
1 shared publicationFurong Lv
Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1509-1525
AI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy
Purpose: To explore the diagnostic and prognostic value of AI-quantified MRI tumor volume for assessing pathologic response in unresectable hepatocellular carcinoma (uHCC) after hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy (HAIC-TI). Materials and Methods: This retrospective study included 35 patients (46 lesions) who underwent HAIC-TI followed by hepatectomy. AI was used to calculate the tumor enhancement volume ratio (TEVR) from MRI. Correlation analysis was conducted to evaluate the relationship between TEVR and pathological tissue proportions. Receiver operating characteristic (ROC) curve determined the optimal cutoff for the ratio of viable tumor cells (RVTCs) to define major pathological response (MPR). The diagnostic performance of AI for MPR and its prognostic significance in recurrence-free survival (RFS) were assessed. Results: TEVR in portal venous phase is strongly correlated with non-necrotic tissue ratio (r = 0.89, p < 0.001). RVTCs ≤ 10% predicted reduced intrahepatic recurrence (Area Under the Curve [AUC] = 0.808, p < 0.001) and independently associated with prolonged RFS (HR [hazard ratio] = 0.19, 95% CI [confidence interval]: 0.05– 0.69, p = 0.011). TEVR ≤ 19.5% in the portal venous phase demonstrated high diagnostic performance for identifying MPR (AUC = 0.879) and was significantly associated with improved RFS in both univariable analysis (HR = 0.34, 95% CI: 0.12– 1.00, p = 0.049) and the multivariable model incorporating only clinical and imaging factors. Conclusion: AI-based MRI quantification of TEVR effectively reflected pathologic response and served as a non-invasive prognostic marker for postoperative recurrence in uHCC patients after HAIC-TI. Plain Language Summary: Why was this study done? After receiving combined chemotherapy, targeted therapy, and immunotherapy for liver cancer, doctors need to accurately assess whether the tumor is responding well. Currently, this requires surgically removing the tumor for microscopic examination (pathological analysis), which cannot provide real-time evaluation during treatment. We aimed to use artificial intelligence (AI) to predict treatment effectiveness earlier using routine MRI scans, helping clinicians decide optimal timing for surgery. What did we do? We analyzed data from 35 liver cancer patients treated with this combination therapy. An AI tool measured the tumor enhancement volume ratio (TEVR) on MRI scans and compared it with post-surgery pathology results. We focused on two questions: 1) Can TEVR reflect the proportion of surviving tumor cells? 2) Can TEVR predict postoperative recurrence risk? What did we find? AI-measured TEVR strongly matched pathology findings: When TEVR ≤ 19.5%, tumors had ≤ 10% surviving cells (indicating major treatment response), with 87.9% accuracy in predicting liver recurrence. Patients meeting this threshold had 5 times longer recurrence-free survival time (81% lower risk). This AI method works faster than traditional approaches and avoids additional procedures.
- 1 July 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 1509-1525
Open AccessAI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy
Purpose: To explore the diagnostic and prognostic value of AI-quantified MRI tumor volume for assessing pathologic response in unresectable hepatocellular carcinoma (uHCC) after hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy (HAIC-TI). Materials and Methods: This retrospective study included 35 patients (46 lesions) who underwent HAIC-TI followed by hepatectomy. AI was used to calculate the tumor enhancement volume ratio (TEVR) from MRI. Correlation analysis was conducted to evaluate the relationship between TEVR and pathological tissue proportions. Receiver operating characteristic (ROC) curve determined the optimal cutoff for the ratio of viable tumor cells (RVTCs) to define major pathological response (MPR). The diagnostic performance of AI for MPR and its prognostic significance in recurrence-free survival (RFS) were assessed. Results: TEVR in portal venous phase is strongly correlated with non-necrotic tissue ratio (r = 0.89, p < 0.001). RVTCs ≤ 10% predicted reduced intrahepatic recurrence (Area Under the Curve [AUC] = 0.808, p < 0.001) and independently associated with prolonged RFS (HR [hazard ratio] = 0.19, 95% CI [confidence interval]: 0.05– 0.69, p = 0.011). TEVR ≤ 19.5% in the portal venous phase demonstrated high diagnostic performance for identifying MPR (AUC = 0.879) and was significantly associated with improved RFS in both univariable analysis (HR = 0.34, 95% CI: 0.12– 1.00, p = 0.049) and the multivariable model incorporating only clinical and imaging factors. Conclusion: AI-based MRI quantification of TEVR effectively reflected pathologic response and served as a non-invasive prognostic marker for postoperative recurrence in uHCC patients after HAIC-TI. Plain Language Summary: Why was this study done? After receiving combined chemotherapy, targeted therapy, and immunotherapy for liver cancer, doctors need to accurately assess whether the tumor is responding well. Currently, this requires surgically removing the tumor for microscopic examination (pathological analysis), which cannot provide real-time evaluation during treatment. We aimed to use artificial intelligence (AI) to predict treatment effectiveness earlier using routine MRI scans, helping clinicians decide optimal timing for surgery. What did we do? We analyzed data from 35 liver cancer patients treated with this combination therapy. An AI tool measured the tumor enhancement volume ratio (TEVR) on MRI scans and compared it with post-surgery pathology results. We focused on two questions: 1) Can TEVR reflect the proportion of surviving tumor cells? 2) Can TEVR predict postoperative recurrence risk? What did we find? AI-measured TEVR strongly matched pathology findings: When TEVR ≤ 19.5%, tumors had ≤ 10% surviving cells (indicating major treatment response), with 87.9% accuracy in predicting liver recurrence. Patients meeting this threshold had 5 times longer recurrence-free survival time (81% lower risk). This AI method works faster than traditional approaches and avoids additional procedures.
- Open Access
- 1 October 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (39) , e27117
Identification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis
Background: Hepatocellular carcinoma (HCC) is the third cancer-related cause of death in the world. Until now, the involved mechanisms during the development of HCC are largely unknown. This study aims to explore the driven genes and potential drugs in HCC. Methods: Three mRNA expression datasets were used to analyze the differentially expressed genes (DEGs) in HCC. The bioinformatics approaches include identification of DEGs and hub genes, Gene Ontology terms analysis and Kyoto encyclopedia of genes and genomes enrichment analysis, construction of protein–protein interaction network. The expression levels of hub genes were validated based on The Cancer Genome Atlas, Gene Expression Profiling Interactive Analysis, and the Human Protein Atlas. Moreover, overall survival and disease-free survival analysis of HCC patients were further conducted by Kaplan–Meier plotter and Gene Expression Profiling Interactive Analysis. DGIdb database was performed to search the candidate drugs for HCC. Results: A total of 197 DEGs were identified. The protein–protein interaction network was constructed using Search Tool for the Retrieval of Interacting Genes software, 10 genes were selected by Cytoscape plugin cytoHubba and served as hub genes. These 10 genes were all closely related to the survival of HCC patients. DGIdb database predicted 29 small molecules as the possible drugs for treating HCC. Conclusion: Our study provides some new insights into HCC pathogenesis and treatments. The candidate drugs may improve the efficiency of HCC therapy in the future.
- 1 October 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (39) , e27117
Open AccessIdentification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis
Background: Hepatocellular carcinoma (HCC) is the third cancer-related cause of death in the world. Until now, the involved mechanisms during the development of HCC are largely unknown. This study aims to explore the driven genes and potential drugs in HCC. Methods: Three mRNA expression datasets were used to analyze the differentially expressed genes (DEGs) in HCC. The bioinformatics approaches include identification of DEGs and hub genes, Gene Ontology terms analysis and Kyoto encyclopedia of genes and genomes enrichment analysis, construction of protein–protein interaction network. The expression levels of hub genes were validated based on The Cancer Genome Atlas, Gene Expression Profiling Interactive Analysis, and the Human Protein Atlas. Moreover, overall survival and disease-free survival analysis of HCC patients were further conducted by Kaplan–Meier plotter and Gene Expression Profiling Interactive Analysis. DGIdb database was performed to search the candidate drugs for HCC. Results: A total of 197 DEGs were identified. The protein–protein interaction network was constructed using Search Tool for the Retrieval of Interacting Genes software, 10 genes were selected by Cytoscape plugin cytoHubba and served as hub genes. These 10 genes were all closely related to the survival of HCC patients. DGIdb database predicted 29 small molecules as the possible drugs for treating HCC. Conclusion: Our study provides some new insights into HCC pathogenesis and treatments. The candidate drugs may improve the efficiency of HCC therapy in the future.
- Open Access
- 2 July 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 697747
Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma
Circular RNAs (circRNAs) are newly classified noncoding RNA (ncRNA) members with a covalently closed continuous loop structure that are involved in immune responses against hepatitis B virus (HBV) infections and play important biological roles in the occurrence and pathogenesis of HCC progression. The roles of circRNAs in HBV-associated HCC (HBV-HCC) have gained increasing attention. Substantial evidence has revealed that both tissue and circulating circRNAs may serve as potential biomarkers for diagnostic, prognostic and therapeutic purposes. So far, at least four circRNA/miRNA regulatory axes such as circRNA_101764/miR-181, circRNA_100338/miR-141-3p, circ-ARL3/miR-1305, circ-ATP5H/miR-138-5p, and several circulating circRNAs were reported to be associated with HBV-HCC development. Notably, TGF/SMAD, JAK/STAT, Notch and Wnt/β-catenin signaling pathways may play pivotal roles in this HBV-driven HCC via several circRNAs. Moreover, in non-HBV HCC patients or HCC patients partially infected by HBV, numerous circRNAs have been identified to be important regulators impacting the malignant biological behavior of HCC. Furthermore, the role of circRNAs in HCC drug resistance has become a focus of research with the aim of reversing chemoresistance and immune resistance. Herein, we review the molecular biology of circRNAs in HBV-HCC and their potential in therapeutic strategies.
- 2 July 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 697747
Open AccessCurrent Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma
Circular RNAs (circRNAs) are newly classified noncoding RNA (ncRNA) members with a covalently closed continuous loop structure that are involved in immune responses against hepatitis B virus (HBV) infections and play important biological roles in the occurrence and pathogenesis of HCC progression. The roles of circRNAs in HBV-associated HCC (HBV-HCC) have gained increasing attention. Substantial evidence has revealed that both tissue and circulating circRNAs may serve as potential biomarkers for diagnostic, prognostic and therapeutic purposes. So far, at least four circRNA/miRNA regulatory axes such as circRNA_101764/miR-181, circRNA_100338/miR-141-3p, circ-ARL3/miR-1305, circ-ATP5H/miR-138-5p, and several circulating circRNAs were reported to be associated with HBV-HCC development. Notably, TGF/SMAD, JAK/STAT, Notch and Wnt/β-catenin signaling pathways may play pivotal roles in this HBV-driven HCC via several circRNAs. Moreover, in non-HBV HCC patients or HCC patients partially infected by HBV, numerous circRNAs have been identified to be important regulators impacting the malignant biological behavior of HCC. Furthermore, the role of circRNAs in HCC drug resistance has become a focus of research with the aim of reversing chemoresistance and immune resistance. Herein, we review the molecular biology of circRNAs in HBV-HCC and their potential in therapeutic strategies.
- Open Access
- 14 October 2020
- Published by Springer Nature in Research Square
Identification of hub genes and potential drugs in hepatocellular carcinoma through integrated bioinformatics analysis
BackgroundHepatocellular carcinoma (HCC) is the third cancer-related cause of death in the world. Until now, the involved mechanisms during the development of HCC are largely unknown. This study aims to explore the driven-genes and potential drugs in HCC. MethodsThree mRNA expression datasets were used to analyze the differentially expressed genes (DEGs) in HCC. The bioinformatics approaches include identification of DEGs and hub genes, GO terms analysis and KEGG enrichment analysis, construction of protein–protein interaction network. The expression levels of hub genes were validated based on TCGA, GEPIA and the Human Protein Atlas. Moreover, overall survival and disease-free survival analysis of the hub genes were further conducted by Kaplan-Meier plotter and the GEPIA. DGIdb database was performed to search the candidate drugs for HCC. ResultsFinally, 197 DEGs were identified. The PPI network was constructed using STRING software. Then ten genes were selected and considered as the hub genes. The ten genes were all closely related to the survival of HCC patients. DGIdb database predicted 39 small molecules as the possible drugs for treating HCC. ConclusionsOur study provides some new insights into HCC pathogenesis and treatments. The candidate drugs may improve the efficiency of HCC therapy in future.
- 14 October 2020
- Published by Springer Nature in Research Square
Open AccessIdentification of hub genes and potential drugs in hepatocellular carcinoma through integrated bioinformatics analysis
BackgroundHepatocellular carcinoma (HCC) is the third cancer-related cause of death in the world. Until now, the involved mechanisms during the development of HCC are largely unknown. This study aims to explore the driven-genes and potential drugs in HCC. MethodsThree mRNA expression datasets were used to analyze the differentially expressed genes (DEGs) in HCC. The bioinformatics approaches include identification of DEGs and hub genes, GO terms analysis and KEGG enrichment analysis, construction of protein–protein interaction network. The expression levels of hub genes were validated based on TCGA, GEPIA and the Human Protein Atlas. Moreover, overall survival and disease-free survival analysis of the hub genes were further conducted by Kaplan-Meier plotter and the GEPIA. DGIdb database was performed to search the candidate drugs for HCC. ResultsFinally, 197 DEGs were identified. The PPI network was constructed using STRING software. Then ten genes were selected and considered as the hub genes. The ten genes were all closely related to the survival of HCC patients. DGIdb database predicted 39 small molecules as the possible drugs for treating HCC. ConclusionsOur study provides some new insights into HCC pathogenesis and treatments. The candidate drugs may improve the efficiency of HCC therapy in future.
- Open Access
- 1 March 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 2193-2203
LINC01296 promotes proliferation, migration, and invasion of HCC cells by targeting miR-122-5P and modulating EMT activity
Introduction: Long noncoding RNAs (lncRNAs) play an important role in the origination and progression of hepatocellular carcinoma (HCC). However, the biological function of the long intergenic non-protein-coding RNA, LINC01296, in HCC remains unknown. Methods: Here, we observed an increase in the expression levels of LINC01296 in HCC tissues and cell lines using reverse transcription quantitative PCR; these data were consistent with that obtained from The Cancer Genome Atlas database. Results: A higher expression level was correlated with higher alpha fetoprotein levels, a larger tumor size, an advanced TNM stage, and a poorer overall survival rate. Upregulation of LINC01296 promoted the proliferation, migration, and invasion of HCC cells. Improvement of cell migration and invasion attributable to the overexpression of LINC01296 was related to an increase in epithelial–mesenchymal transition (EMT). Mechanistically, miR-122-5P can bind to LINC01296 and decrease its oncogenic effect. Conclusion: Collectively, the results of this study revealed that LINC01296 is a tumor promoter that can promote the migration and invasion of HCC cells through EMT, while miR-122-5P is involved in the underlying mechanisms.
- 1 March 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 2193-2203
Open AccessLINC01296 promotes proliferation, migration, and invasion of HCC cells by targeting miR-122-5P and modulating EMT activity
Introduction: Long noncoding RNAs (lncRNAs) play an important role in the origination and progression of hepatocellular carcinoma (HCC). However, the biological function of the long intergenic non-protein-coding RNA, LINC01296, in HCC remains unknown. Methods: Here, we observed an increase in the expression levels of LINC01296 in HCC tissues and cell lines using reverse transcription quantitative PCR; these data were consistent with that obtained from The Cancer Genome Atlas database. Results: A higher expression level was correlated with higher alpha fetoprotein levels, a larger tumor size, an advanced TNM stage, and a poorer overall survival rate. Upregulation of LINC01296 promoted the proliferation, migration, and invasion of HCC cells. Improvement of cell migration and invasion attributable to the overexpression of LINC01296 was related to an increase in epithelial–mesenchymal transition (EMT). Mechanistically, miR-122-5P can bind to LINC01296 and decrease its oncogenic effect. Conclusion: Collectively, the results of this study revealed that LINC01296 is a tumor promoter that can promote the migration and invasion of HCC cells through EMT, while miR-122-5P is involved in the underlying mechanisms.
- Retracted
- 29 December 2017
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 32 (4) , 298-303
RETRACTED: Liver X Receptors Activation Attenuates Ischemia Reperfusion Injury of Liver Graft in Rats
Purpose: Suppression of the Toll like receptor 4 (TLR4)-nuclear factor-κB (NF-κB) signaling was critical in protection against liver IRI. Previous studies revealed that Liver X receptors (LXRs) activation could antagonize TLR4-NF-κB signaling. The purpose of this study is to determine whether LXRs agonist GW3965 can suppress the TLR4-NF-κB signaling during liver transplantation and protect ischemia-reperfusion injury (IRI). Materials and Methods: Sprague Dawley (SD) rats were used to perform orthotropic liver transplantation. Donors were pretreatment with GW3965 (0.3 mg/kg) through caudal vein injection 30 min before the surgery. The followings were analyzed after transplantation: alanine aminotransferase (ALT), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) level in serum, ATP binding cassette transporter A1 (Abca1) expression, NF-κB transcriptional activity, apoptosis and histological injury. Results: GW3965 pretreatment significantly ameliorated the degree of IRI associated with the effects of upregulating Abca1 expression, inhibiting NF-κB transcriptional activity, and downregulating TNF-α and IL-6 level. Conclusion: LXRs activation attenuated hepatic IRI by preventing TLR4–NF-κB signaling.
- 29 December 2017
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 32 (4) , 298-303
RetractedRETRACTED: Liver X Receptors Activation Attenuates Ischemia Reperfusion Injury of Liver Graft in Rats
Purpose: Suppression of the Toll like receptor 4 (TLR4)-nuclear factor-κB (NF-κB) signaling was critical in protection against liver IRI. Previous studies revealed that Liver X receptors (LXRs) activation could antagonize TLR4-NF-κB signaling. The purpose of this study is to determine whether LXRs agonist GW3965 can suppress the TLR4-NF-κB signaling during liver transplantation and protect ischemia-reperfusion injury (IRI). Materials and Methods: Sprague Dawley (SD) rats were used to perform orthotropic liver transplantation. Donors were pretreatment with GW3965 (0.3 mg/kg) through caudal vein injection 30 min before the surgery. The followings were analyzed after transplantation: alanine aminotransferase (ALT), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) level in serum, ATP binding cassette transporter A1 (Abca1) expression, NF-κB transcriptional activity, apoptosis and histological injury. Results: GW3965 pretreatment significantly ameliorated the degree of IRI associated with the effects of upregulating Abca1 expression, inhibiting NF-κB transcriptional activity, and downregulating TNF-α and IL-6 level. Conclusion: LXRs activation attenuated hepatic IRI by preventing TLR4–NF-κB signaling.
- Open Access
- 1 May 2017
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 16 (5) , 7649-7656
MicroRNA-340 inhibits tumor cell proliferation, migration and invasion, and induces apoptosis in hepatocellular carcinoma
MicroRNAs (miRs) are short RNAs that serve a role in the origination and progression of hepatocellular carcinoma (HCC). miR‑340 has been identified to be a novel tumor suppressor. The present study investigated the antitumor function of miR‑340 in HCC. In the present study, it was detected that miR‑340 was significantly decreased in HCC cancer tissues and human HCC cell lines using reverse transcription‑quantitative polymerase chain reaction analysis. Cell Counting kit‑8 and apoptosis assays demonstrated that miR‑340 reduced cell proliferation and induced cellular apoptosis in HCC cell lines. A Transwell invasion assay demonstrated that miR‑340 suppressed the migration and invasion of HCC cell lines. In addition, S‑phase kinase‑associated protein 2 (SKP2), which may be repressed by miR‑340 in HCC cell lines, was identified to be a potential target of miR‑340. The results of the present study revealed that miR‑340 serves a tumor suppressor role by influencing the proliferation, apoptosis, migration and invasion of HCC cell lines, which may be explained by the downregulation of SKP2 by miR‑340.
- 1 May 2017
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 16 (5) , 7649-7656
Open AccessMicroRNA-340 inhibits tumor cell proliferation, migration and invasion, and induces apoptosis in hepatocellular carcinoma
MicroRNAs (miRs) are short RNAs that serve a role in the origination and progression of hepatocellular carcinoma (HCC). miR‑340 has been identified to be a novel tumor suppressor. The present study investigated the antitumor function of miR‑340 in HCC. In the present study, it was detected that miR‑340 was significantly decreased in HCC cancer tissues and human HCC cell lines using reverse transcription‑quantitative polymerase chain reaction analysis. Cell Counting kit‑8 and apoptosis assays demonstrated that miR‑340 reduced cell proliferation and induced cellular apoptosis in HCC cell lines. A Transwell invasion assay demonstrated that miR‑340 suppressed the migration and invasion of HCC cell lines. In addition, S‑phase kinase‑associated protein 2 (SKP2), which may be repressed by miR‑340 in HCC cell lines, was identified to be a potential target of miR‑340. The results of the present study revealed that miR‑340 serves a tumor suppressor role by influencing the proliferation, apoptosis, migration and invasion of HCC cell lines, which may be explained by the downregulation of SKP2 by miR‑340.
- 1 February 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 38 (2) , 652-664
The function of miRNAs in hepatocarcinogenesis induced by hepatitis B virus X protein
MicroRNAs are short RNAs that play a crucial role in all biological processes through post-transcriptional regulation for protein-coding genes and inducing mRNA degradation. Hepatitis B virus infection has been considered as a major risk factor in hepatocellular carcinoma, further research indicates that hepatitis B virus X protein (HBx) is one of the critical links of hepatocarcinogenesis. HBx takes part in hepatocarcinogenesis via regulating transcription, signal transduction, apoptosis, protein degradation and DNA repair. miRNA is the important target gene of HBx, their interaction impacts many tumor processes, such as proliferation, apoptosis, invasion, metastasis, differentiation and adipogenesis. In the present study we reviewed the current state of knowledge of regulation pathway of HBx acting on miRNAs, and focused on the role of their interplay in hepatocarcinogenesis.
- 1 February 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 38 (2) , 652-664
The function of miRNAs in hepatocarcinogenesis induced by hepatitis B virus X protein
MicroRNAs are short RNAs that play a crucial role in all biological processes through post-transcriptional regulation for protein-coding genes and inducing mRNA degradation. Hepatitis B virus infection has been considered as a major risk factor in hepatocellular carcinoma, further research indicates that hepatitis B virus X protein (HBx) is one of the critical links of hepatocarcinogenesis. HBx takes part in hepatocarcinogenesis via regulating transcription, signal transduction, apoptosis, protein degradation and DNA repair. miRNA is the important target gene of HBx, their interaction impacts many tumor processes, such as proliferation, apoptosis, invasion, metastasis, differentiation and adipogenesis. In the present study we reviewed the current state of knowledge of regulation pathway of HBx acting on miRNAs, and focused on the role of their interplay in hepatocarcinogenesis.
- Open Access
- 20 October 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (6) , 4931-4941
Post-translational modifications of FOXO family proteins
The Forkhead box O (FOXO) protein family is predominantly involved in apoptosis, oxidative stress, DNA damage/repair, tumor angiogenesis, glycometabolism, regulating life span and other important biological processes. Its activity is affected by a variety of posttranslational modifications (PTMs), including phosphorylation, acetylation, ubiquitination, methylation and glycosylation. When cells are subjected to different environments, the corresponding PTMs act on the FOXO protein family, to change transcriptional activity or subcellular localization, and the expression of downstream target genes, will ultimately affect the biological behavior of the cells. In this review, we will discuss the biological characteristics of FOXO protein PTMs.
- 20 October 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (6) , 4931-4941
Open AccessPost-translational modifications of FOXO family proteins
The Forkhead box O (FOXO) protein family is predominantly involved in apoptosis, oxidative stress, DNA damage/repair, tumor angiogenesis, glycometabolism, regulating life span and other important biological processes. Its activity is affected by a variety of posttranslational modifications (PTMs), including phosphorylation, acetylation, ubiquitination, methylation and glycosylation. When cells are subjected to different environments, the corresponding PTMs act on the FOXO protein family, to change transcriptional activity or subcellular localization, and the expression of downstream target genes, will ultimately affect the biological behavior of the cells. In this review, we will discuss the biological characteristics of FOXO protein PTMs.
- Open Access
- 1 January 2015
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 21, 1864-1871
Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma
BACKGROUND:Recently, increasing research evidence indicates that miRNA plays important roles in oncogenesis of hepatocellular carcinoma (HCC). The objective of this study was to investigate the potential of plasma miRNAs as biomarkers for HCC determi...
- 1 January 2015
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 21, 1864-1871
Open AccessPlasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma
BACKGROUND:Recently, increasing research evidence indicates that miRNA plays important roles in oncogenesis of hepatocellular carcinoma (HCC). The objective of this study was to investigate the potential of plasma miRNAs as biomarkers for HCC determi...